Amgen Inc.

Marc Vimolratana

Sean P Brown

Jonathan B Houze

Julio Cesar Medina

Liusheng Zhu

Ming Yu

Paul John Dransfield

Yingcai Wang

Todd J Kohn

Wang Shen

Zice Fu

Jiwen Liu

Xianghong Wang

Joshua Taygerly

Vatee Pattaropong

Mike Elias Lizarzaburu

Yunxiao Li

Manuel Zancanella

SuJen Lai

Zhihua Ma

Ana Zurisadai Gonzalez Buenrostro

Zhihong Li

Zhongyu Wang

Nick A Paras

Michael J Schmitt

Xian Yun Jiao

XianYun Jiao

Xiaohui Du

Rajiv Sharma

Hilary Plake Beck

Brian Stuart Lucas

An-Rong Li

Jinqian Liu

Jian Luo

Xuelei Yan

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Alan C Cheng

Mario G Cardozo

Jason A Duquette

Kexue Li

Gayathri Swaminath

Jie Zhang

Michael R Degraffenreid

Jiasheng Fu

YuMei Xiong

Michael W Gribble, Jr

Yongli Su

Jiang Zhu

Yong-Jae Kim

Margrit Schwarz

Jeffrey D Reagan

David Karl Bedke

Qiong Cao

Daniel Lin

Li Yang

Ana Gonzalez Buenrostro

Mike Elias Lizazaburu

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit Mcl-1 protein

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I&#x2032;B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Spirocyclic GPR40 modulators

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Substituted biphenyl GPR40 modulators

Heterocyclic GPR40 modulators

Growing community of inventors

New York, NY, United States of America

Marc Vimolratana